tiprankstipranks
Cerevel Therapeutics Holdings (CERE)
NASDAQ:CERE

Cerevel Therapeutics Holdings Stock Analysis & Ratings

CERE Stock Chart & Stats

Day’s Range$23.29 - $25.56
52-Week Range$12.01 - $46.16
Previous Close$23.9
Volume441.69K
Average Volume (3M)459.10K
Market Cap$3.74B
P/E Ratio-15.3
Beta3.28
Next EarningsAug 10, 2022
Next Dividend Ex-DateN/A
Dividend YieldN/A
Smart Score8
EPS (TTM)-1.65


Financials

Yearly

P/E Ratio Range

The price to earnings ratio. This is used by investors to assess a stock’s market price relative to its earnings.

---

Risk Analysis

Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products

Product Monthly Users

Sorry, No Data Available
There is no website visitor data available for this stock.

---

CERE FAQ

What was Cerevel Therapeutics Holdings’s price range in the past 12 months?
Cerevel Therapeutics Holdings lowest stock price was $12.01 and its highest was $46.16 in the past 12 months.
    What is Cerevel Therapeutics Holdings’s market cap?
    Cerevel Therapeutics Holdings’s market cap is $3.74B.
      What is Cerevel Therapeutics Holdings’s price target?
      The average price target for Cerevel Therapeutics Holdings is $48.25. This is based on 4 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
      The highest analyst price target is $50.00 ,the lowest forecast is $44.00. The average price target represents 91.47% Increase from the current price of $25.2.
        What do analysts say about Cerevel Therapeutics Holdings?
        Cerevel Therapeutics Holdings’s analyst rating consensus is a ‘Strong Buy. This is based on the ratings of 4 Wall Streets Analysts.
          When is Cerevel Therapeutics Holdings’s upcoming earnings report date?
          Cerevel Therapeutics Holdings’s upcoming earnings report date is Aug 10, 2022 which is in 85 days.
            How were Cerevel Therapeutics Holdings’s earnings last quarter?
            Cerevel Therapeutics Holdings released its earnings results on May 10, 2022. The company reported -$0.46 earnings per share for the quarter, missing the consensus estimate of -$0.425 by -$0.035.
              Is Cerevel Therapeutics Holdings overvalued?
              According to Wall Street analysts Cerevel Therapeutics Holdings’s price is currently Undervalued.
                Does Cerevel Therapeutics Holdings pay dividends?
                Cerevel Therapeutics Holdings does not currently pay dividends.
                What is Cerevel Therapeutics Holdings’s EPS estimate?
                Cerevel Therapeutics Holdings’s EPS estimate for its next earnings report is not yet available.
                How many shares outstanding does Cerevel Therapeutics Holdings have?
                Cerevel Therapeutics Holdings has 148,290,000 shares outstanding.
                  What happened to Cerevel Therapeutics Holdings’s price movement after its last earnings report?
                  Cerevel Therapeutics Holdings reported an EPS of -$0.46 in its last earnings report, missing expectations of -$0.425. Following the earnings report the stock price went up 2.254%.
                    Which hedge fund is a major shareholder of Cerevel Therapeutics Holdings?
                    Among the largest hedge funds holding Cerevel Therapeutics Holdings’s share is Perceptive Advisors LLC. It holds Cerevel Therapeutics Holdings’s shares valued at 178M.

                      ---

                      Cerevel Therapeutics Holdings Stock Analysis

                      Smart Score
                      8
                      Outperform
                      1
                      2
                      3
                      4
                      5
                      6
                      7
                      8
                      9
                      10
                      Price Target
                      $48.25
                      ▲(91.47% Upside)
                      Strong Buy
                      The Cerevel Therapeutics Holdings stock analysis is based on the TipRanks Smart Score which is derived from 8 unique data sets including Analyst recommendations, Crowd Wisdom, Hedge Fund Activity, Media Sentiment and multiple Technical stock factors. The Smart Score is a quantitative, data-driven rating system and does not include human intervention.
                      Learn more about TipRanks Smart Score

                      Company Description

                      Cerevel Therapeutics Holdings

                      ARYA Sciences Acquisition Corp II is a blank check company.

                      ---
                      Similar Stocks
                      No data currently available

                      Popular Stocks

                      ---
                      What's Included in PREMIUM?
                      Make informed decisions based on Top Analysts' activity
                      Know what industry insiders are buying
                      Get actionable alerts from top Wall Street Analysts
                      Find out before anyone else which stock is going to shoot up
                      Get powerful stock screeners & detailed portfolio analysis